pete_nash said:ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase…
Saving this. It is the first explanation that did not require me to already understand it.
Adding the clinical framing, because it changes how the question reads. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.
paige_pharma said:NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The objection nobody has made: this only works if the measurement is doing what we assume it is doing, and that assumption has not been tested here.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsThe figures, for anyone assembling their own picture. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.
Happy to go further on any of that.
Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful.